Last reviewed · How we verify
NCT06811194: PRIME
PRIor Myocardial Infarction Identification on Electrocardiogram
trial in Prior Myocardial Infarction in 12,000 participants. Enrolling by invitation.
20 February 2026
Quick facts
| Lead sponsor | The Third People's Hospital of Chengdu |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 12,000 |
| Start date | 20 February 2025 |
| Primary completion | 20 February 2026 |
| Estimated completion | 20 February 2031 |
| Sites | 1 location across China |
Conditions studied
- Prior Myocardial Infarction — all drugs for Prior Myocardial Infarction →
Sponsor
The Third People's Hospital of Chengdu
Who can join
Adults 35 to 85, any sex, with Prior Myocardial Infarction. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Abstract Background: Chronic myocardial infarction (MI) is a serious cardiovascular disease associated with high mortality rates, making early diagnosis and timely intervention essential for improving patient outcomes. However, some patients may present without clear symptoms or relevant medical histories, complicating the diagnostic process. Currently, diagnosis predominantly relies on electrocardiograms (ECGs) and imaging tests. Although cardiac magnetic resonance imaging (MRI) is regarded as the gold standard, its high cost and complexity hinder its clinical application. Consequently, there is an urgent need for new ECG diagnostic criteria to mitigate the risks of misdiagnosis and missed diagnoses. Objective: This study aims to explore new diagnostic criteria to enhance the accuracy of ECG diagnoses for chronic MI. Methods: This research is a prospective, multicenter cohort study designed to assess the impact of newly developed ECG diagnostic criteria on the accuracy of chronic myocardial infarction (MI) diagnoses. The study spans a 60-month period, including a 12-month patient enrollment phase. Participants will comprise individuals aged 35 to 85 who meet the inclusion criteria: those diagnosed with chronic myocardial infarction via ECG, those with a definitive history of MI (≥3 months), or individuals clinically suspected of having coronary artery disease with at least two coronary risk factors. Data collection will include clinical symptoms, signs, ECG findings, and cardiac magnetic resonance (CMR) findings, the latter serving as a primary endpoint. Follow-up will focus on changes in patients' symptoms and ECG assessments. Statistical analysis software will be employed to evaluate the influence of the new diagnostic criteria on rates of missed and misdiagnosis.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06811194
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other The Third People's Hospital of Chengdu trials
Trials by the same sponsor.
- NCT07321002 — PFLotus With the DePolar Mapping System in Patients With Persistent Atrial Fibrillation · NA · not yet recruiting
- NCT07301190 — FIH Study of PFLotus in Persistent Atrial Fibrillation · NA · recruiting
- NCT06699368 — Clinical Study on the Risk of Left Atrial POP Ablation and Esophageal Injury Under Ultra-High Power and Related Influenc · NA · not yet recruiting
- NCT06694610 — A Study on the Relationship Between Individualized Low Voltage Regions in Left Atrium and the Mechanism of Atrial Fibril · NA · not yet recruiting
- NCT06652750 — Evaluating the Safety and Effectiveness of 5G Cloud Follow-up for Cardiovascular Implantable Electronic Devices · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06811194 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Third People's Hospital of Chengdu
- Last refreshed: 6 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06811194.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing